{"id":"W4389229234","doi":"10.1182/blood-2023-186773","title":"ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Nilotinib; Bosutinib; Medicine; Dasatinib; Discontinuation; Tolerability; Internal medicine; Adverse effect; Oncology; Myeloid leukemia; Imatinib","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002665749,0.001443013,0.001774021,0.0005878892,0.0005622169,0.001524124,0.001298312,0.001927735,0.007532205],"category_scores_gemma":[0.001380213,0.0004328895,0.002385596,0.0005067934,0.0009031921,0.001409719,0.0006452673,0.004424304,0.001340636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00155284,"about_ca_system_score_gemma":0.002111416,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000814277,"about_ca_topic_score_gemma":0.003466662,"domain_scores_codex":[0.9994586,0.0002337743,0.00003464487,0.00006945954,0.00006428597,0.0001390982],"domain_scores_gemma":[0.9983052,0.0002697949,0.0003828055,0.00008909458,0.0001525467,0.0008005031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7387317,0.04203458,0.006323022,0.002434339,0.002324688,0.000287063,0.0003518867,0.002413838,0.01277554,0.0009230355,0.01617412,0.1752261],"study_design_scores_gemma":[0.7390821,0.2386061,0.007423919,0.0001972754,0.00080907,0.000340741,0.00009178097,0.0008494512,0.002067572,0.0006265885,0.009865475,0.00003985049],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9625921,0.01556765,0.00105428,0.003720709,0.0006132805,0.005294544,0.005336919,0.0003242958,0.005496326],"genre_scores_gemma":[0.9501446,0.009223715,0.005612978,0.005779203,0.0007246626,0.00924295,0.0120231,0.00007058194,0.007178191],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007532205,"threshold_uncertainty_score":0.02519774,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03765564633306478,"score_gpt":0.32515279904201,"score_spread":0.2874971527089452,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}